Will antirheumatic treatment improve cardiovascular outcomes in patients with rheumatoid arthritis?

Current Pharmaceutical Design

Volumn 20, Issue 4, 2014, Pages 486-495

  Pieringer, Herwig ^a,b   Pichler, Max ^b   Pohanka, Erich ^a,c   Hoppe, Uta C ^b  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiovascular disease; Rheumatoid arthritis; Treatment outcomes

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DISEASE MARKER; HUMAN; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR TARGETED THERAPY; RHEUMATOID VASCULITIS; TREATMENT OUTCOME;

EID: 84894046029     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990712     Document Type: Article

References (127)

1. Huizinga TW, Pincus T. In the clinic Rheumatoid arthritis. Ann Intern Med 2010; 153: ITC1-1-ITC1-15; quiz ITC1-16.
2. Prete M, Racanelli V, Digiglio L, Vacca A, Dammacco F, Perosa F. Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev 2011; 11: 123-31
3. Pieringer H, Pichler M. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 2011; 104: 13-26
4. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7
5. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46: 862-873
6. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63
7. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a populationbased study. Arthritis Rheum 2005; 52: 722-32
8. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52: 2293-9
9. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999; 100: 2124-6
10. Mellana WM, Aronow WS, Palaniswamy C, Khera S. Rheumatoid arthritis: cardiovascular manifestations, pathogenesis, and therapy. Curr Pharm Des 2012; 18: 1450-6
11. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 2010; 8: 437-49
12. Smolen JS, Aletaha D. Developments in the clinical understanding of rheumatoid arthritis. Arthritis Res Ther 2009; 11: 204
13. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin-ExpRheumatol 2005; 23: S100-8
14. Rho YH, Chung CP, Oeser A, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009; 61: 1580-5
15. Wållberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapää-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002; 29: 875-82
16. Bisoendial RJ, Levi M, Tak PP, Stroes ES. The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardiovascular events. SeminThrombHemost 2010; 36: 452-7
17. Wållberg-Jonsson S, Cederfelt M, RantapääDahlqvist S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol 2000; 27: 71-5
18. Gasparyan AY, Stavropoulos-Kalinoglou A, Toms TE, Douglas KM, Kitas GD. Association of mean platelet volume with hypertension in rheumatoid arthritis. Inflamm Allergy Drug Targets 2010; 9: 45-50
19. Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and metaanalysis. J ThrombHaemost 2010; 8: 148-56
20. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011; 17: 47-58
21. Lanati N, Emanuele E, Brondino N, Geroldi D. Soluble RAGEmodulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. CurrVascPharmacol 2010; 8: 86-92
22. Chiang KH, Huang PH, Huang SS, Wu TC, Chen JW, Lin SJ. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients. Coron Artery Dis 2009; 20: 267-73
23. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005; 7: R817-24
24. Dimitroulas T, Giannakoulas G, Karvounis H, Garyfallos A, Settas L, Kitas G. B-type natriuretic peptide in rheumatic diseases: a cardiac biomarker or a sophisticated acute phase reactant? Autoimmun Rev 2012; 11: 837-43
25. Dimitroulas T, Sandoo A, Kitas GD. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. Int J Mol Sci 2012; 13: 12315-35
26. rd, et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol 2011; 38: 29-35
27. Wasko MC, Kay J, Hsia EC, Rahman MU. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken). 2011; 63: 512-21
28. Hashimoto J, Westerhof BE, Westerhof N, Imai Y, O'Rourke MF. Different role of wave reflection magnitude and timing on left ventricular mass reduction during antihypertensive treatment. J Hypertens 2008; 26: 1017-24
29. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31: 1865-7
30. Pieringer H, Schumacher S, Stuby U, Biesenbach G. Augmentation index and large-artery remodeling in patients with longstanding rheumatoid arthritis compared with healthy controls. Semin Arthritis Rheum 2009; 39: 163-9.
31. Pieringer H, Brummaier T, Schmid M, et al. Rheumatoid Arthritis Is an Independent Risk Factor for an Increased Augmentation Index Regardless of the Coexistence of Traditional Cardiovascular Risk Factors. Semin Arthritis Rheum 2012; 42: 17-22.
32. Mäki-Petäjä KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006; 114: 1185-92
33. Kocabay G, Hasdemir H, Yildiz M. Evaluation of pulse wave velocity in systemic lupus erythematosus, rheumatoid arthritis and Behçet's disease. J Cardiol 2012; 59: 72-7
34. Faulx MD, Wright AT, Hoit BD. Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am Heart J 2003; 145: 943-51
35. ChatterjeeAdhikari M, Guin A, Chakraborty S, Sinhamahapatra P, Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum 2012; 41: 669-75
36. vanSijl AM, Peters MJ, Knol DK, et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 2011; 40: 389-97
37. Södergren A, Karp K, Boman K, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010; 12: R158
38. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007; 48: 751-62
39. Dixon WG, Symmons DP. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007; 66: 1132-6
40. Mattey DL, Glossop JR, Nixon NB, Dawes PT. Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 3940-8
41. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J 1993; 70: 141-3
42. Arvidson NG, Larsen A, Aaseth J, Larsson A. Short-term effects of the TNFalpha antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis. Scand J Clin Lab Invest. 2007; 67: 337-42
43. Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin-ExpRheumatol 2010; 28: 254-7
44. Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 2008; 31: 175-9
45. Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol 2010; 6: 445-51
46. Wasko MC, Kay J, Hsia EC, Rahman MU. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken) 2011; 63: 512-21
47. Antohe JL, Bili A, Sartorius JA, et al. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy. Arthritis Care Res (Hoboken) 2012; 64: 215-21
48. Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-TNF therapy. Arthritis Care Res (Hoboken) 2012; 64: 1282-91.
49. Schimmel EK, Yazici Y. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience. ClinExpRheumatol 2009; 27: 446-51
50. Onat A, Direskeneli H. Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Des 2012; 18: 1465-77
51. Peters MJ, Welsh P, McInnes IB, et al. Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis 2010; 69: 1281-5
52. Sandoo A, Dimitroulas T, Toms TE, et al. Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis. Clin Biochem 2012; 45: 1399-403
53. Dulai R, Perry M, Twycross-Lewis R, Morrissey D, Atzeni F, Greenwald S. The Effect of Tumor Necrosis Factor-α Antagonists on Arterial Stiffness in Rheumatoid Arthritis: A Literature Review. Semin Arthritis Rheum. 2012; 42(1): 1-8.
54. Kerekes G, Soltész P, Szucs G, et al. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J 2011; 13: 147-52
55. Capria A, De Nardo D, Baffetti FR, et al. Long-term anti-TNFalpha treatments reverse the endothelial dysfunction in rheumatoid arthritis: the biological coherence between synovial and endothelial inflammation. Int J Immunopathol Pharmacol 2010; 23: 255-62
56. Giles JT, Post WS, Blumenthal RS, et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2011; 63: 3216-25
57. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-8
58. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006; 55: 531-6
59. Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 3790-8
60. Dixon WG, Watson KD, Lunt M, Hyrich KL. British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-12
61. Greenberg JD, Kremer JM, Curtis JR, et al. CORRONA Investigators. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 576-82
62. Al-Aly Z, Pan H, Zeringue A, et al. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res 2011; 157: 10-8
63. Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011; 50: 518-31
64. Barnabe C, Martin BJ, Ghali WA. Systematic review and metaanalysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63: 522-9
65. Peters MJ, van Sijl AM, Voskuyl AE, Sattar N, Smulders YM, Nurmohamed MT. The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis. Curr Pharm Des 2012; 18: 1502-11
66. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72
67. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379: 1214-24
68. Hirao M, Yamasaki N, Oze H, et al. Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab. Rheumatol Int 2012; 32: 4041-5.
69. Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PloS One. 2010 Dec 13; 5(12): e14328
70. Kawashiri SY, Kawakami A, Yamasaki S, et al. Effects of the antiinterleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011; 31: 451-6
71. Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol 2011; 38: 2169-71
72. Protogerou AD, Zampeli E, Fragiadaki K, et al. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 2011; 219: 734-6
73. Novikova DS, Popkova TV, Nasonov EL. The effect of anti-B-cell therapy on the development of atherosclerosis in patients with rheumatoid arthritis. Curr Pharm Des 2012; 18: 1512-8
74. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002; 109: 745-53
75. Kyaw T, Tipping P, Toh BH, Bobik A. Current understanding of the role of B cell subsets and intimal and adventitial B cells in atherosclerosis. Curr Opin Lipidol 2011; 22: 373-9
76. Raterman HG, Levels H, Voskuyl AE, Lems WF, Dijkmans BA, Nurmohamed MT. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis 2013; 72: 560-5.
77. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 2008; 59: 1821-4
78. Kerekes G, Soltész P, Dér H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009; 28: 705-10
79. Mathieu S, Pereira B, Dubost JJ, Lusson JR, Soubrier M. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology (Oxford) 2012; 51: 1107-11
80. Arts EE, Jansen TL, Den Broeder A, et al. Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2011; 70: 877-8
81. Ennishi D, Asai H, Maeda Y, et al. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2010; 21: 1217-21
82. Nowakowski GS, Maurer MJ, Habermann TM, et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010; 28: 412-7
83. Kume K, Amano K, Yamada S, Hatta K. Tocilizumab Improves Arterial Stiffness Compared with Abatacept In Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. An Open Label Randomized Controlled Trial. [abstract]. Arthritis Rheum 2011; 63 Suppl 10: 395
84. Mathieu S, Szymanski G, Dubost JJ, et al. Assessment of Cardiovascular Markers after 24 Weeks of Abatacept or Rituximab Therapy in Patients with Rheumatoid Arthritis. [abstract]. Arthritis Rheum 2010; 62 Suppl 10: 375
85. Weyand CM, Younge BR, Goronzy JJ. T cells in arteritis and atherosclerosis. CurrOpinLipidol 2008; 19: 469-77
86. Weyand CM, Goronzy JJ, Liuzzo G, Kopecky SL, Holmes DR Jr, Frye RL. T-cell immunity in acute coronary syndromes. Mayo Clin Proc 2001; 76: 1011-20
87. Pryshchep S, Goronzy JJ, Parashar S, Weyand CM. Insufficient deactivation of the protein tyrosine kinase lck amplifies T-cell responsiveness in acute coronary syndrome. Circ Res 2010; 106: 769-78
88. Bulgarelli A, Martins Dias AA, Caramelli B, Maranhão RC. Treatment with methotrexate inhibits atherogenesis in cholesterolfed rabbits. J Cardiovasc Pharmacol 2012; 59: 308-14
89. Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 2006; 8(3): R82
90. Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 2002; 4: R12
91. Toms TE, Panoulas VF, John H, Douglas KM, Kitas GD. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60-more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 2009; 11: R110
92. Ristić GG, Lepić T, Glisić B, et al. Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment. Rheumatology (Oxford) 2010; 49: 1076-81
93. Landewé RB, van den Borne BE, Breedveld FC, Dijkmans BA. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000; 355: 1616-7
94. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7
95. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010; 49: 295-307
96. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108: 1362-70
97. Coomes E, Chan ES, Reiss AB. Methotrexate in atherogenesis and cholesterol metabolism. Cholesterol 2011; 2011: 503028
98. Chen DY, Chih HM, Lan JL, Chang HY, Chen WW, Chiang EP. Blood lipid profiles and peripheral blood mononuclear cell cholesterol metabolism gene expression in patients with and without methotrexate treatment. BMC Med 2011; 9: 4
99. vanHalm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8(5): R151
100. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10(2): R30
101. Rozman B, Praprotnik S, Logar D, et al. Leflunomide and hypertension. Ann Rheum Dis 2002; 61: 567-9
102. Serelis J, Panagiotakos DB, Mavrommati M, Skopouli FN. Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: a Greek cohort study. J Rheumatol 2011; 38: 236-41
103. Nauman J, Janszky I, Vatten LJ, Wisløff U. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA 2011; 306: 2579-87
104. Bili A, Sartorius JA, Kirchner HL, et al. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol 2011; 17: 115-20
105. Penn SK, Kao AH, Schott LL, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2010; 37: 1136-42
106. Morris SJ, Wasko MC, Antohe JL, et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2011; 63(4): 530-4
107. Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 374-7
108. Chrisman OD, Snook GA, Wilson TC, Short JY. Prevention of venous thromboembolism by administration of hydroxychloroquine. A preliminary report. J Bone Joint Surg Am 1976; 58: 918-20
109. Tanay A, Leibovitz E, Frayman A, Zimlichman R, Shargorodsky M, Gavish D. Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. Ann N Y Acad Sci 2007; 1108: 24-34
110. Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168
111. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90: 859-65
112. Buttgereit F. Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis? Ann Rheum Dis 2011; 70: 1881-3
113. rd, Hunder GG, Gabriel SE. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia. Arthritis Rheum 2007; 57: 279-86
114. Pieringer H, Stuby U, Hargassner S, Biesenbach G. Treatment with corticosteroids reduces arterial stiffness in patients with polymyalgia as measured with pulse wave analysis. Ann Rheum Dis 2008; 67: 279
115. Ravindran V, Rachapalli S, Choy EH. Safety of medium-to longterm glucocorticoid therapy in rheumatoid arthritis: a metaanalysis. Rheumatology (Oxford) 2009; 48: 807-11
116. Ruyssen-Witrand A, Fautrel B, Saraux A, Le Loët X, Pham T. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011; 78: 23-30
117. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086
118. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PloS Med 2011; 8(9): e1001098
119. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-44
120. Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009; 68: 367-72
121. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31
122. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70: 482-7
123. Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 2012; 18: 1543-55
124. Crowson CS, Liang KP, Therneau TM, Kremers HM, Gabriel SE. Could accelerated aging explain the excess mortality in patients with seropositive rheumatoid arthritis? Arthritis Rheum 2010; 62: 378-82
125. Gonzalez A, Icen M, Kremers HM, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol 2008; 35: 1009-14
126. Gonzalez A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56: 3583-7
127. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011; 70: 8-14